About AN2 THERAPEUTICS, INC
AN2 Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel small-molecule therapeutics using a boron chemistry platform for rare, chronic, and serious infectious diseases, as well as hematologic and oncology indications. The company is committed to addressing critical unmet medical needs.
Development of novel small-molecule therapeutics using a boron chemistry platformPipeline spanning hematologic diseases, infectious diseases, and oncologyAdvanced research programs targeting oncology, bone disorders, and infectious diseases
Recent Federal Awards
| Award | Agency | Amount | Date |
|---|---|---|---|
| DEVELOPMENT OF EPETRABOROLE AS A NOVEL THERAPEUTIC FOR MELIOIDOSIS AND ADDITIONAL ANTIMICROBIAL RESISTANT (AMR | Department of Health and Human Services | $9.2M |
Is this your company?
Claim this profile to keep it accurate — and see the federal & state opportunities GovIntel's AI has matched to AN2 THERAPEUTICS, INC right now.
Claim this profile See matched opportunitiesData compiled from public government sources including SAM.gov, USAspending.gov, and state procurement records. Last verified against federal award records. Inaccurate? Let us know.